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Background and objectives: Malignant hyperthermia (MH) is a pharmacogenetic disease that 
causes abnormal hypermetabolic reaction to halogenated anesthetics and/or depolarizing muscle 
relaxants. In Brazil, there is a hotline telephone service for MH since 1991, available 24 hours a day 
in São Paulo. This article analyzes the activity of the Brazilian hotline service for MH in 2009.
Methods: Prospective analysis of all phone calls made to the Brazilian hotline service for MH from 
January to December 2009.
Results: Twenty-two phone calls were received: 21 from the South/Southeast region of Brazil 
and one from the North region. Fifteen calls were requests for general information about MH. 
Seven were about suspected MH acute episodes, two of which were not considered as MH. In ﬁ ve 
episodes compatible with MH, all patients received halogenated volatile anesthetics (2, isoﬂ urane; 
3, sevoﬂ urane) and one also used succinylcholine; there were four men and one woman, with a 
mean age of 18 years (2-27). The problems described in the ﬁ ve MH episodes were tachycardia 
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(5), increased expired carbon dioxide (4), hyperthermia (3), acidemia (1), rhabdomyolysis (1), 
and myoglobinuria (1). One patient received dantrolene. All ﬁ ve patients with MH episodes were 
follow-up in the intensive care unit and recovered without sequelae. Susceptibility to MH was 
later conﬁ rmed in two patients by in vitro muscle contracture test.
Conclusions: The number of calls per year in the Brazilian hotline service for MH is still low. The 
characteristics of MH episode were similar to those reported in other countries. The knowledge 
of MH in Brazil needs to be increased.
© 2013 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda.   
Introduction
Malignant hyperthermia (MH) is a pharmacogenetic disorder 
with autosomal dominant inheritance, characterized by ab-
normal hypermetabolic response to inhalational anesthetics 
(halogenated group) and depolarizing muscle relaxants, such 
as succinylcholine 1. Typical episodes feature tachycardia, 
tachypnea, hypercarbia, muscle rigidity, hyperthermia, met-
abolic acidosis, and rhabdomyolysis. However, there is great 
clinical variability, with abortive, atypical or fulminant forms, 
and even isolated masseter spasm 1,2. MH also has genetic 
variation: approximately 50% to 70% of cases are associated 
with ryanodine receptor gene mutations (a calcium release 
channel from the sarcoplasmic reticulum into the cytoplasm 
of the muscle ﬁ ber), but mutations have been described 
in other genes related to calcium metabolism, such as the 
dihydropyridine receptor gene 3,4. MH was ﬁ rst described 
in 1960 and occurs at frequencies up to 1:10,000 general 
anesthesias in children and 1:50,000 in adults 2. The ﬁ rst 
report on MH in Brazil occurred during halothane anesthesia 
and was published in 1975 5. However, there is no data on 
the actual incidence of MH in Brazil, a continental country 
with 190 million inhabitants 5. Considering the 3,890,755 
anesthesias performed at the Uniﬁ ed Health System (SUS) in 
2009 and 1:50,000 frequency of MH episodes during general 
anesthesia in adults, one would expect at least 77 reports 
of MH episodes during this period 6.
In 1991, a service for MH was created in Brazil called 
Hotline (+55-11-55759873), which is available 24 hours per 
day. The Brazilian hotline service for MH is located in the 
city of São Paulo at Hospital São Paulo, Escola Paulista de 
Medicina, Universidade Federal de São Paulo (EPM/Unifesp) 7. 
Between 1991 and 2008, phone calls to the hotline were di-
rected to the Division of Surgical Intensive Care and answered 
by the intensive care staff, assisted by MH supervisors. Since 
2009, phone calls have been redirected to a group consist-
ing of two supervisors - also specialized in MH investigation 
(HCAS, neurologist - and JLGA, anesthesiologist) - and eight 
doctors. The physicians received training that consisted of 
an intensive course on MH, with theoretical and practical 
information. Training included dantrolene dissolution and 
diagnostic test for MH susceptibility, through in vitro muscle 
contracture test (IVCT) in response to halothane and caf-
feine, which is available at the Center for Study, Diagnosis 
and Investigation of Malignant Hyperthermia (Cedhima), 
Hospital São Paulo (EPM/Unifesp).
The objective of this study is to analyze the activity of 
the Brazilian hotline service for MH in 2009.
Material and methods
This was a prospective, analytical and observational study. 
The study’s primary material was the attendance records 
of the Brazilian hotline service for MH in 2009. These at-
tendance records consisted of data identifying the caller, 
call location (city, state, hospital service, or residence), 
return phone number, description of call reason, proposed 
solution, consultant identiﬁ cation, and date. For classiﬁ ca-
tion, two independent investigators analyzed each record. 
Initially, categorization and tabulation of data on call loca-
tion, caller, description of call reason, and solution proposed 
were performed. For records in which the call reason was a 
suspected episode of MH, we used a clinical scale described 
by Larach et al. 8 to grade the likelihood of MH. This scale 
should not be used to make a diagnosis of MH susceptibility, 
but serves to classify the severity of episodes. In this 1- to 
6-point scale (from almost incompatible to almost certain), 
MH suspected episodes are classiﬁ ed according to points 
obtained when analyzing the following variables: muscle 
rigidity, rhabdomyolysis, hyperthermia, cardiac abnormal-
ity, acid-base changes, and response to treatment with 
dantrolene 8. The study secondary material was the medical 
records of patients who, after being notiﬁ ed of the Brazilian 
hotline service for MH in 2009, were referred to Cedhima 
for evaluation/investigation and provided signed informed 
consent (CEP 0970/08). Data collected from medical records 
were demographic; medical, family, and epidemiologic his-
tory; current complaints; general physical examination; 
neurological examination; and laboratory tests, including 
histopathological study of muscle with histochemistry and 
in vitro muscle contracture test in response to halothane 
and caffeine. Histopathological study of muscle included the 
following reactions and staining: hematoxylin-eosin, periodic 
acid-Schiff (PAS), modiﬁ ed Gomori trichrome, Sudan black B; 
succino dehydrogenase (SDH), cytochrome C-oxidase (COX), 
nicotinamide adenine dinucleotide tetrazolium reductase 
(NADH), and adenosine triphosphatase (ATPase) acidic (pH 
4.3) and alkaline (pH 9.4), according to the methodology 
described by Dubowitz 9. 
In vitro muscle contracture test in response to halothane 
and caffeine was performed according to the protocol of the 
European Malignant Hyperthermia Group (www.emhg.org) 10. 
After biopsy, four fragments (0.5x2 cm) of vastus lateralis 
muscle are immediately placed into a Krebs-Ringer’s solution 
(95% oxygen and 5% carbon dioxide) and dissected into thin 
fragments (2-3 mm) under stereomicroscope (Olympus, USA). 
Then, each fragment is attached to a silver electrode at one 
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end and to a force transducer at the other (transducer Narco 
Bio Systems, International Biomedical, USA). Tests are made 
in baths heated to 37°C, through thermostatically controlled 
circulating water (Mecânica Castro Saraiva, Brazil), ﬁ lled with 
Krebs-Ringer’s solution and continuously carboxygenated. 
Each fragment is continuously stimulated with supramaximal 
electrical pulses of 1 ms and frequency of 0.2 Hz (Boeck 
stimulator). The degree of muscle contraction is monitored 
in real time during the entire test and detected by force 
transducer linked to an IBM 486 computer, using an ampli-
ﬁ er/analog-digital converter and program for biological data 
acquisition AqDados (Links, Brazil). At least four tests are 
performed for each patient: two with caffeine and two with 
halothane. To test caffeine, concentrations of 0.5, 1.0, 1.5, 
2.0, 3.0, 4.0 and 32.0 mmol.L-1 are used. To test halothane, 
the concentrations are 0.5, 1.0, 2.0 and 3.0%. Test results are 
referred to as the threshold, which is the lowest concentration 
of caffeine and halothane producing a minimum increase of 
0.2 g in basal tension. 
According to test results, patients are classiﬁ ed into 
three groups:
a)  Malignant hyperthermia susceptibility (MHS): caf-
feine threshold concentration of 2.0 mmol or less and 
halothane threshold of 2.0% or less;
b)  Malignant hyperthermia nonsusceptible (MHN): caf-
feine threshold concentration of 3.0 mmol or more 
and halothane threshold of 3.0% or more;
c)  Malignant hyperthermia equivocal (MHE): other re-
sults are considered equivocal. 
From a practical standpoint, MHE patients are also con-
sidered susceptible to MH.
Results
In 2009, the Brazilian hotline service for MH received 22 calls: 
21 from the South/Southeast region and one from the North 
region (Pará State). The Southeast region had 17 calls, all 
from the State of São Paulo, and the Southern region had four 
calls, three from Paraná and one from Rio Grande do Sul.
Among the 22 calls, 15 were requests for general informa-
tion about MH and seven about suspected MH acute episodes. 
General information consisted on how to purchase dantrolene 
(4), how to research MH susceptibility (3), and how to obtain 
additional information about the disease (8). For the general 
information, proposed solutions were, respectively: contact the 
customer service department (SAC) of the lab selling dantrolene 
in Brazil (Cristália: +55-11-0800 7011 918); seek MH outpatient 
clinic to schedule a visit (telephone +55-11-55719667); and visit 
Cedhima’s website (MH section) at www.anestesiologia.unifesp.
br. The additional information requested by the eight callers 
were: how to assemble a hospital kit of MH; who may have MH; 
which is the safe anesthesia for MH; where to ﬁ nd literature 
on MH for school work; and, ﬁ nally, if halothane exhaled by 
a pet dog after surgery could be dangerous for susceptible 
individuals to MH. The ﬁ rst three information are available on 
Cedhima’s MH section, while the fourth information initially 
recommended keeping the animal in the veterinary clinic 
during postoperative period and, subsequently, a consultation 
with MHAUS (Malignant Hyperthermia Association of the United 
States: www.mhaus.org.br) was done and it was suggested to 
follow the recommendation of the MHAUS consensus about 
the lack of risk,  to susceptible individuals, associated with 
residual anesthetic in the operating room air, provided there 
is the necessary exhaustion. Table 1 shows the distribution of 
calls by caller’s characteristic.
Among the seven patients with suspected MH acute 
episode, three calls came from the hospital that houses the 
Brazilian hotline service for MH; afterwards, two of these 
patients underwent investigation and susceptibility to MH 
was conﬁ rmed. Given that 16,865 anesthetic procedures were 
performed at Hospital São Paulo (EPM/Unifesp) in 2009 (in-
cluding anesthetics for surgeries and diagnostic procedures), 
the presence of two MH episodes would indicate, in this serv-
ice, a frequency of 1.1:10,000. Of these, 8,906 were general 
anesthesia, which would imply a MH episode frequency of 2.2 
per 10,000 general anesthesia cases in this service.
Considering the seven patients with suspected MH episode 
after reviewing the history and additional tests required, 
in two of them the episodes were not considered as MH. 
One patient had not used triggering agents (halogenated 
or succinylcholine), and the event was later diagnosed as a 
reaction to fentanyl. The other patient had postoperative 
hyperthermia and sepsis was diagnosed.
All ﬁ ve patients whose episode was considered compatible 
with MH underwent anesthesia with halogenated anesthet-
ics (2 with isoﬂ urane, 3 with sevoﬂ urane); one patient also 
received succinylcholine. This group consisted of four men 
and one woman, mean age 18 years (range 2-27). Surgeries 
performed were orthopedic (1), ENT (ears, nose, throat) sur-
gery (1), gastrointestinal (2), and thoracic (1). The problems 
described in these ﬁ ve patients during the MH episode were, in 
order of frequency: tachycardia (5 patients: mean of 130 bpm, 
range of 120-140 bpm); increase in expired carbon dioxide (4 
patients: mean of 70 mm Hg, range of 52-96 mm Hg); hyper-
thermia (3 patients: mean of 39.5°C, range of 39-40°C); 
acidemia (1 patient: pH 7.22); rhabdomyolysis (2 patients: 
CPK 4,701-27,037 U.L-1); and choluria (1 patient). According 
to the clinical grading scale to assess the likelihood of MH 8, 
these ﬁ ve MH episodes had a mean score of 28 points (range 
18-43). Table 2 presents the clinical grading scale to assess 
the likelihood of MH 8 and anesthetics used in ﬁ ve patients.
Relatives of two of the patients considered compatible 
with MH reported that deaths had occurred during anesthesia 
in other family members.
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Guidance to MH compatible individuals was done ac-
cording to the informed characteristic of the episode and 
standardized treatment protocol 1,2. In four patients, MH 
episode ceased with discontinuation of triggering halogen-
ated agents and measures such as cooling (2 patients) and hy-
perventilation with 100% oxygen (2 patients); in one patient 
(number 3) dantrolene was administered. All ﬁ ve patients 
were monitored in the intensive care unit and recovered 
without sequelae; two of them were referred for evaluation 
and investigation at Cedhima (patients 2 and 4) and will be 
described in detail below.
Patient 2: male, aged 27 years, ASA I, with history of tu-
mor mass in the left thigh, whose biopsy diagnosed alveolar 
sarcoma. The patient received four cycles of chemotherapy 
(ifosfamide and doxorubicin), which have been completed 
10 months ago, and subsequently amputation was required of 
the left lower limb. The patient was later diagnosed with lung 
metastasis and underwent right pulmonary metastasectomy 
four months ago. Both previous surgeries were performed 
under combined/balanced general anesthesia, uneventful, 
and halogenated isoﬂ urane was used in both surgeries.
Subsequently, a new pulmonary metastasectomy was in-
dicated (now to the left), with balanced/combined general 
anesthesia induced with midazolam, fentanyl, propofol, and 
atracurium. Isoﬂ urane (up to 1 MAC) in addition to epidural 
anesthesia were used for maintenance. After induction, the 
patient evolved to persistent and unexplained sinus tachycar-
dia, normothermia, and maximum expired CO2 of 52 mm Hg 
(Figure 1). Postoperatively, the patient developed diffuse 
myalgia and choluria. Serum creatine phosphokinase (CPK) 
levels were measured on the third postoperative day and 
showed a value of 27,037 U.L-1 (normal value 190 U.L-1), which 
raised the hypothesis of postoperative rhabdomyolysis due to 
MH. The patient evolved without further complications; was 
discharged from the ICU on the sixth day, informed about 
his possible susceptibility to MH, and referred to Cedhima’s 
outpatient clinic.
On physical and neurological examination during outpa-
tient evaluation, the patient presented diminished breathing 
sounds in the left hemithorax and left lower limb amputation 
at thigh level. CPK value was 258 U.L-1. After four months of 
hospital discharge, the patient underwent right vastus lateralis 
muscle biopsy for in vitro muscle contracture test in response 
to halothane and caffeine. Two tests with halothane showed 
contracture (0.24 g and 0.48 g, concentration of 2%), which 
is consistent with positive results, indicating susceptibility to 
MH. Histopathological examination of skeletal muscle showed 
mild subsarcolemmal mitochondrial proliferation. Since the MH 
episode, the patient had already undergone two lung metasta-
sectomies under total intravenous anesthesia, uneventfully.
Patient 4: female, aged 23 years, ASA I, with history of left 
patella chronic dislocation since 11 years old after fall from 
own height. The patient had undergone three previous un-
eventful surgical procedures (varus osteotomy, femorodistal 
pseudo-arthrodesis, and medial patellofemoral reconstruc-
tion), all on the left side. In the preanesthetic evaluation, 
the patient denied signiﬁ cant family history.
Subsequently, the patient was admitted for revision 
of left femur osteosynthesis evaluation, and general an-
esthesia was chosen, given the time scheduled for the 
procedure. Concomitant epidural anesthesia was initially 
attempted; however, due to accidental dural puncture, 
this procedure was abandoned. General anesthesia was 
induced with sufentanil, propofol, and pancuronium, with 
isoﬂ urane and sufentanil used for maintenance. After four 
hours of uneventful surgery, without apparent surgical 
reasons, the patient showed increased capnometric values 
(up to 66 mm Hg, conﬁ rmed with arterial blood gas, also 
showing respiratory acidosis); tachycardia (121 bpm); and 
ETCO2: end-tidal carbon dioxide; mmHg: millimeters of mercury; T: 
temperature; °C: degrees Celsius; HR: heart rate; bpm: beats per 
minute; h: hours.










ETCO2 (mmHg) T (ºC) HR (bpm)
9h 10h 11h 12h 13h 14h 15h
Table 2  Clinical Grading Scale Score for MH Probability 8 versus Anesthetics Used in Five Brazilian Patients.
Score Theoretical probability Theoretical risk of 
MH
Patients and score (n) Triggering anesthetic
0 Almost impossible 1 0
3 to 9 Unlikely 2 0




20 to 34 Somewhat more than likely 4 Patient 3: 28 Sevoﬂ urane + 
succinylcholine




50 or + Almost certain 6 0
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temperature elevation (baseline: 36ºC, maximum reached 
40ºC, intraesophageal temperature sensor). The diagnosis of 
malignant hyperthermia was then hypothesized by the an-
esthesiologist, and the proposed measures were taken 1,2,7. 
The surgical team was notiﬁ ed of the suspected diagnosis 
and the maintenance anesthesia was replaced by exclusively 
intravenous injection of propofol via an infusion pump and 
opioid fentanyl, when necessary). Additionally, infusion 
of cold saline and hyperventilation with oxygen 100% was 
started, with improvement within minutes following these 
measures. After surgery and uneventful extubation in the 
operating room, the patient was transferred to the ICU 
for 48 hours. CPK showed progressive elevation from the 
surgery, with maximum of 4,701 U.L-1, two days after sur-
gery, but with gradual return to baseline. The patient was 
discharged on the sixth day after the procedure, asympto-
matic, informed about the suspected susceptibility to MH, 
and referred to Cedhima’s outpatient clinic.
During outpatient evaluation, the patient reported a his-
tory of exhertion intolerance, with cramps, in addition to 
congenital clubfoot. She reported several changes in her fam-
ily: son with inguinal hernia; father with pectus carinatum, 
clubfoot, and chronic patellar dislocation; paternal aunt and 
grandmother with chronic patellar dislocation; ﬁ rst-degree 
cousin who died during surgery. On physical and neurologi-
cal examination, the patient presented short neck, bilateral 
ptosis, and arched palate. Serum CPK was increased at rest 
(1,061 U.L-1). Three months after discharge, she underwent 
right vastus lateralis muscle biopsy for in vitro muscle con-
tracture test in response to halothane and caffeine. There 
was contracture in two tests with halothane (3.6 g and 1.56 g, 
concentration of 2%; Figure 2) and two tests with caffeine 
(2.92 g and 1.2 g, concentration of 2 mmol; Figure 3) com-
patible with positive results, indicating susceptibility to MH. 
Pathological examination of skeletal muscle showed sparse 
ﬁ bers with various changes, such as necrosis, hypertrophy, 
centralization or segmentation.
Discussion
Calls to MH hotline were mostly from the Southeast Region 
and within the State of São Paulo. This ﬁ nding may be due 
to the fact that the hotline service is located in São Paulo 
and because there is speciﬁ c legislation for MH in this state, 
which requires notiﬁ cation of the MH episodes and dantrolene 
availability 11-14. On the other hand, the complete lack of calls 
from the states of Rio de Janeiro and Santa Catarina could be 
explained by the centralization of services related to MH in 
these states (Universidade Federal do Rio de Janeiro and the 
Universidade Federal de Santa Catarina, respectively) 1,7.
However, it is more difﬁ cult to explain the lack of calls 
from the Northeast and Midwest regions, from Minas Gerais 
and Espírito Santo States, as well as a single call from the 
Northern region. With the increased level of suspicion, it is 
possible that more MH diagnoses will be made, as occurred 
in the hotline service for MH. In the past, MH was believed 
as being exclusive to Caucasians, which has proven to be 
incorrect with the description of MH episode in BLACKS, 
Orientals, and Indians 15-17. In Brazil, the initial impression 
that the MH genetic trait would be concentrated in European 
descendants in the south has also been disproved by genetic 
studies, such as the description of a patient from Minas Gerais 
who was compound heterozygous (i.e., an individual with 
two different mutations in their ryanodine receptor, each 
inherited from one of the non-consanguineous parents) 18. 
This ﬁ nding from the work of Kossugue et al. 18 conforms 
the estimated frequency of the ryanodine gene mutation in 
ryanodine carriers, which could reach up to 1:2000 19. This 
prevalence would be much higher than the estimated rate 
for MH episode – explained by the fact that many mutation 
carriers are never anesthetized with triggering drugs and, 
even if exposed, they may not develop a MH episode, as oc-
curred in patient 2 of this report 20.
%: Percentage. Arrows indicate the time at which the drug was 
added.
Figure 2  In Vitro Muscle Contracture Test in Response to 
Halothane (patient 4).
g: gram; min: minutes; mmol.L-1: millimoles per liter. Arrows indi-
cate the time at which the drug was added.
Figure 3  In Vitro Muscle Contracture Test in Response to 
Caffeine (patient 4).
Halothane    0,5            1           2          3%
Caffein    0,5     1      1,5      2         3          4       mMol/L
0,4g
1 min
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Much of the calls were requests for information, which 
is understandable due to MH rarity, with characteristics of 
an orphan disease. Orphan diseases are rare and affect a 
small number of individuals and/or have no treatment that 
stimulates the interest of industry investments, diagnosis, 
and treatment 21.
Regarding dantrolene issues, in Brazil there is a 
Resolution of the Federal Council of Medicine (Resolution CFM 
1.802/2006), which includes dantrolene on the list of “drugs 
that should necessarily be available in any setting where 
anesthesia is used” 22. Considering an individual weighing 
70 kg and a loading dose of dantrolene 2.5 mg.kg-1, nine vials 
of dantrolene 20 mg would be required for the ﬁ rst bolus. 
Because bolus is repeated until the MH episode is controlled 
and up to 10 mg.kg-1 (4 boluses) may be needed to control 
it, 36 vials of dantrolene should be kept in stock. This stock 
must be immediately available to anesthesiologists, as the 
time to dilute dantrolene can reach 4 minutes per vial and the 
mortality rate is demonstrated to increase when the ﬁ rst dose 
is administered 30 minutes after the onset of the episode 23,24. 
Furthermore, there is a need for options for quickly acquir-
ing additional dantrolene, in case there is a need for more 
than 10 mg.kg-1 of dantrolene to control a episode, a need 
to continue treatment for 24-48 hours, and the  increasingly 
common possibility of overweight patients.
MH differential diagnosis includes various conditions that 
may lead to hypercapnia (problems in the ventilation circuit), 
hypermetabolism (pheochromocytoma, thyrotoxic episode, 
exogenous intoxication with salicylates), and/or hyperthermia 
(iatrogenic heating, sepsis). Although MH may occur postop-
eratively, it is unlikely that fever alone characterizes MH 25. 
Another cause for excluding MH diagnosis in hotline calls in 
2009 was an isolated reaction characterized by muscle rigid-
ity after opioid use, a rare event associated with high doses, 
which occurs during induction or recovery and may show 
improvement after naloxone or neuromuscular block 26.
Regarding MH episode presentation in our country, there 
are similarities with those reported in other countries. The 
halogenated agents involved were sevoﬂ urane and isoﬂ urane. 
Keep in mind that all halogenated agents may cause MH, even 
when the patient has not received succinylcholine 27. There 
was a clear predominance of male (80%), as well as young 
patients, similar to the recent revision by Larach et al. 24, 
which reports 74.8% of men with mean age of 22 years. The 
higher frequency of episodes in men, a disease that has au-
tosomal dominant inheritance (i.e., not sex-linked), has been 
explained by the greater muscle mass in males. The higher 
frequency in young people may be correlated with increased 
use of halogenated agents in this population.
We should emphasize that in the present report two 
families had a history of anesthetic problems that were not 
reported to the anesthesiologist before the procedure, which 
reinforces the importance of exhaustive investigation of any 
suggestive history during preoperative evaluation.
The fact that all ﬁ ve patients with an episode compatible 
with MH had a good outcome, even with only one of them receiv-
ing dantrolene, is unusual and cannot be considered representa-
tive of the reality in Brazil, as the hotline notiﬁ cation is voluntary. 
In the United States, where the frequency of MH episodes have 
been increasing, mortality rates due to MH vary between 1.4% 
and 22%, even with all the available treatment 28-30.
The non-use of dantrolene in some reports may be associ-
ated with difﬁ culty in obtaining the drug in some locations 
or instant improvement of abortive’s episode with discon-
tinuation of halogenated agents. However, patients who 
do not receive dantrolene, even without presenting with 
cardiorespiratory arrest, are at risk for complications, such 
as liver failure or myalgia and rhabdomyolysis, as the case 
with patient 2 of this report 24.
Regarding clinical features associated with susceptibility 
to MH, several authors have reported osteoarticular changes 
(chronic dislocation, clubfoot), dimorphisms (cleft palate, 
ptosis, strabismus), and myopathies (central core myopathy). 
In this study, patient 4 illustrates this association, with a his-
tory of multiple dimorphisms and presence of osteoarticular 
changes over four generations 1,7,17.
Conclusions
Considering Brazil as a whole, the number of calls to the 
hotline service for MH is still small for a one-year period 
and there is a large concentration in the Southeast region. 
Moreover, the frequency of calls was proportionally much 
higher in the hospital housing the hotline service, probably 
due to the continuing education programs developed there. 
Awareness of MH in Brazil needs to be increased, in addition 
to actions already implemented (regular insertion of MH 
theme in anesthesiology meetings; production of updated 
material, such as books and Brazilian guidelines for MH, and 
development of electronic site for MH: http://www.unifesp.
br/dcir/anestesia/hipertermiamaligna/index.html). 
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